Genitourinary Cancers

Researchers examined whether a higher Gleason score impacts the efficacy of androgen deprivation therapy.

A new study compared two chemotherapy/radiotherapy approaches with regard to distant metastasis–free survival in bladder cancer.

The PURE-01 study showed that neoadjuvant pembrolizumab before surgery could downstage disease in muscle-invasive bladder cancer patients.

Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.

The findings of this study, recently published in JAMA Oncology, directly contradict previously conducted research on the same topic.

Oncologists now have some clarification on the use of moderate hypofractionation and ultrahypofractionation from ASTRO, ASCO, and the AUA.

A study shows stage III renal cell carcinoma patients with nodal disease may need to be reclassified.

A study shows RCC patients overall response rate did not decline from the first‐line to the fourth‐line of IO therapy.

Treatment for prostate cancer with external beam radiotherapy was found to be associated with an increased risk for development of bladder cancer when compared with radical prostatectomy.

This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.

Measures of frailty and comorbidity failed to offer predictive information regarding complications in patients with bladder cancer undergoing radical cystectomy.

New research in Lancet Oncology confirms previous studies in this population on the addition of apalutamide to androgen deprivation therapy.

A study in Cancer found a lower risk of prostate cancer–specific death and improved overall survival when patients were treated with this combination.

A radiographic measure may help clinicians distinguish between benign renal oncocytoma and chromophobe renal cell carcinoma.

A study shows T1a RCC patients have improved overall survival when receiving partial nephrectomy compared with radical nephrectomy.

New research suggests that immune resistance in urothelial cancer may be mediated by stromal cells, which act as a source of EMT-related gene expression.

By elevating the expression of ANO7, a potential prostate cancer susceptibility gene, it may be possible to predict disease severity and outcome.

A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients.

This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.

A particular gatekeeper-the nuclear pore protein called POM121-traffics molecules that increase tumor aggressiveness in prostate cancer.

ZHX2 has been identified as a possible new therapeutic target for clear cell RCC patients.

Concentrations of KIM-1 in the blood may predict for renal cell carcinoma up to 5 years prior to diagnosis.

Cross-sectional, long-term imaging is shown to be important for patients with high-risk resected non–clear cell RCC.

A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.

An existing body of literature shows that marital status and related social support are connected with disease outcomes.